Effects of etamsylate on equine platelets: In vitro and in vivo studies

Segura, Dídac; Monreal, Luís; Pérez-Pujol, Sı́lvia; Alonso, A.; Díaz‐Ricart, Maribel; Brugués, R; Ordinas, Antonio; Escolar, Ginés

doi:10.1016/j.tvjl.2006.06.002

Cited by 12 publications

(8 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Etamsylate is a prohemostatic drug that has been demonstrated to produce moderate platelet activation in horses 14 and humans 15 and a significant shortening of TBT in human, experimental animals, and cattle 4–6 , a . However, no statistically significant differences were observed in our horses on comparing mean TBT before and after etamsylate administration.…”

Section: Discussionmentioning

confidence: 99%

Poor Reproducibility of Template Bleeding Time in Horses

Segura

Monreal

2008

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background: Template bleeding time (TBT) is considered to be a useful test for detecting platelet function disorders and the effect of platelet-activating drugs, but studies in human medicine have concluded that the test has poor reproducibility and sensitivity.Hypothesis: TBT has poor reproducibility in horses and has insufficient sensitivity to detect the effect of etamsylate on platelet function.Animals: Twenty healthy horses. Methods: TBT was determined and repeated 2 hours and 30 days later. TBT was also performed 2 hours after IV administration of etamsylate.Results: Although no statistical differences were seen between the TBT values obtained at different times, the coefficients of variation for TBT replicates ranged from 26.8% to 45.5%. The reference range for TBT was 138.4-860.4 seconds. No statistically significant shortening of the mean TBT value was observed after etamsylate administration.Conclusion and Clinical Importance: TBT has poor reproducibility, and the reference range is too wide to make TBT useful in a clinical setting. Other tests with higher reproducibility should be considered when assessing platelet function disorders in horses.

show abstract

Section: Discussionmentioning

confidence: 99%

Poor Reproducibility of Template Bleeding Time in Horses

Segura

Monreal

2008

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…13 Finally, platelet activation has been described in horses after the administration of some drugs, such as ethamsylate. 14 Recognition of platelet activation specifically, sensitively, and quickly would improve the clinical manage-ment of these horses by allowing the establishment of proper treatment and better follow-up, as well as a more accurate prognosis. Nowadays, detection of platelet membrane receptors, such as P-selectin, by flow cytometry techniques is the most accurate and sensitive method of assessment of platelet activation in whole blood, and it has been evaluated in different physiologic and clinical conditions in humans, small animals, and horses.…”

mentioning

confidence: 99%

“…Nowadays, detection of platelet membrane receptors, such as P-selectin, by flow cytometry techniques is the most accurate and sensitive method of assessment of platelet activation in whole blood, and it has been evaluated in different physiologic and clinical conditions in humans, small animals, and horses. [14][15][16][17][18][19][20][21] However, it is expensive and technically demanding and is not performed routinely.…”

mentioning

confidence: 99%

Mean Platelet Component as an Indicator of Platelet Activation in Foals and Adult Horses

Segura

Monreal

Armengou

et al. 2007

Veterinary Internal Medicne

Self Cite

View full text Add to dashboard Cite

Background: Mean platelet component (MPC) is a new platelet variable, measured by modern commercial complete blood count analyzers, that is reduced during platelet activation in humans and small animals.Hypothesis: MPC decreases in horses with clinical conditions that cause platelet activation and disseminated intravascular coagulation (DIC).Animals: We obtained 418 CBCs from 100 sick and 20 healthy neonates and 178 sick and 45 sound adult horses. Sick neonates were classified into septic and nonseptic, and DIC and non-DIC groups. Adults were grouped by diagnoses (systemic inflammatory disorders, gastrointestinal problems, and thrombocytopenia).Methods: MPC together with platelet count, mean platelet volume, platelet distribution width, and platelet component distribution width were measured with a commercial analyzer and compared between the different disease and control groups in neonates and in adults.Results: MPC values were significantly lower in the septic and nonseptic neonates (24.0 6 3.5 g/dL and 26.6 6 2.6 g/dL, respectively) than in the control group (28.1 6 1.7 g/dL). Neonates with DIC had the lowest MPC values (23.8 6 6.3 g/dL). MPC values in adult horses were significantly lower in the inflammatory (23.5 6 4.7 g/dL), gastrointestinal obstruction (23.0 6 5.0 g/dL), enteritis (23.6 6 4.6 g/dL), ischemic (23.9 6 5.1 g/dL), and thrombocytopenia (20.2 6 5.7 g/dL) groups when compared with control horses (26.2 6 3.5 g/dL). Other platelet variables were not different between the control and the disease groups.Conclusion and Clinical Importance: MPC might be a useful variable for quickly and easily detecting platelet activation in sick neonates and adult horses.

show abstract

“…ETSL is a commonly used clinical hemostatic drug to stop bleeding in surgery, and the main action mechanism is the promotion of platelet adhesion, aggregation and activation, and the release of thrombolytic active substances from platelets to promote vasoconstriction, leading to the activation of coagulation and hemostatic effect. Segura et al showed that ETSL increased P-selectin expression and leukocyte-platelet aggregate formation both in vitro and in vivo (Segura et al, 2007). In total, 20 differential proteins with significant changes were detected in urinary proteome; among them, nine proteins were known disease biomarkers and 13 proteins had human counterparts, including nine proteins in human core urinary proteome (Nagaraj and Mann, 2011).…”

Section: Discussionmentioning

confidence: 99%

Proteome Analysis of Urinary Biomarkers in Acute Hypercoagulable State Rat Model

Jing

Qin

2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

Thrombotic diseases are usually preceded by a hypercoagulable state in the body. This study aimed to screen potential urinary biomarkers for hypercoagulable state based on proteome analysis. Wistar rats were administered with the hemostatic agent etamsylate to establish hypercoagulable state. Urine samples were collected for proteome analysis. We found 20 proteins with levels more than 1.5-fold in difference between control rats and model rats. We searched human homologs of 20 rat proteins and identified 13 human proteins. Of the 13 human homologous proteins, nine were members of human core urinary proteome. Human homologous proteins of differential proteins were highly expressed in 31 human tissues, especially in the kidneys followed by digestive system and reproductive system. Surprisingly, we did not identify known coagulation factors as differential proteins in the urine of model rats. Hypercoagulable state of the body may not involve direct changes in coagulation factors but causes the changes upstream of the coagulation cascade system. Common differential urinary proteins between different hypercoagulable states suggest some common pathways in the formation of hypercoagulable states and may serve as potential biomarkers for the prevention and treatment of thrombotic diseases.

show abstract

Effects of etamsylate on equine platelets: In vitro and in vivo studies

Cited by 12 publications

References 24 publications

Poor Reproducibility of Template Bleeding Time in Horses

Poor Reproducibility of Template Bleeding Time in Horses

Mean Platelet Component as an Indicator of Platelet Activation in Foals and Adult Horses

Proteome Analysis of Urinary Biomarkers in Acute Hypercoagulable State Rat Model

Contact Info

Product

Resources

About